Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to show that thalidomide at a dose of 100 mg/d (with remedial
treatment with dexamethasone if a progression occurs) is equivalent in terms of efficacy with
thalidomide at 400 mg/d (with remedial treatment with dexamethasone if a progression occurs)
in the treatment of refractory or relapsed multiple myeloma after at least two courses of
treatment. The use of thalidomide at 100 mg/d should reduce the side effects and improve the
safety of the treatment.